Shares of McKesson Corp. MCK slipped 1.10% to $586.08 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.88% to 6,049.24 and ...

McKesson's strategic growth in oncology, biopharma and tech drives momentum in 2025. Will MCK overcome its sustaining challenges with robust finances and innovation?

McKesson's stock appears undervalued, trading at 18 times forward earnings and free cash flow. See why MCK is a Hold.

Park Avenue Securities LLC lessened its position in McKesson Co. (NYSE:MCK – Free Report) by 2.5% during the fourth quarter, according to the company in its most recent filing with the Securities & ...

McKesson, which is headquartered in Irving, Texas, operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International.

The National Community Pharmacists Association’s Innovation Center has formed the Independent Community Pharmacy Consortium for Government Engagement, bringing together pharmacy services ...

Evercore ISI analyst Elizabeth Anderson CFA reiterated a Buy rating on McKesson (MCK – Research Report) yesterday and set a price target of ...

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

With a market cap of $74.3 billion, Irving, Texas-based McKesson Corporation (MCK) is a global healthcare services and ...

McKesson (NYSE:MCK – Get Free Report) had its price objective cut by Citigroup from $713.00 to $677.00 in a research note ...